IRStrategy
Strategic Consulting, Reputation & IR
National, Commercial, Public
LHS Immersion messaging and positioning platform identified valuation gaps and opportunity to create value through spinning off subsidiary, Lucid Diagnostics. Early commercial success with opportunity to tell a broader story in esophageal cancer diagnosis along with other innovative medical technologies. Support for IPO process, IR and Corporate Communications for two companies
LHS Solution
- Executive and board member interviews; external review; competitive analysis
- Facilitation of management discussion around recommendations
- Messaging and positioning review
- Blueprint planning around milestones, timelines and execution plan
- On-going Institutaitonal outreach ahead of banker selection and IPO kick off
- Media outreach and strategic placement in local media with KOL and corporate placements
Results
- Stock increased dramatically once IPO announced in March 2021
- Filing for $100M IPO of Lucid Diagnostics with closing expected
- Accelerator model includes launch of subsidiary model, including Veris Health in digital health arena and device to add to portfolio of esophageal products
- Increased visibility and corporate reputation in medical technology arena
- Supported subsidiary, Lucid Diagnostics $100 million IPO that closed in October, 2021 valued at ~$500M, contributing to PAVmed’s valuation of ~$600M
